<DOC>
	<DOCNO>NCT00002109</DOCNO>
	<brief_summary>To confirm result previous study combination thymopentin plus zidovudine ( AZT ) , antiretroviral agent , slow disease progression HIV-infected asymptomatic patient . To evaluate efficacy safety thymopentin HIV-infected asymptomatic patient receive either monotherapy AZT , didanosine ( ddI ) , stavudine ( d4T ) , combination antiretroviral therapy AZT / ddI AZT / zalcitabine ( ddC ) .</brief_summary>
	<brief_title>Double-Blind Study Timunox ( Thymopentin ) Asymptomatic HIV-Infected Patients Receiving Either Mono ( AZT ddI ) Combination ( AZT / ddI AZT / ddC ) Anti-Retroviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Thymopentin</mesh_term>
	<criteria>Inclusion Criteria Patients must : Asymptomatic HIV infection . CD4 count 100400 cells/mm3 . No HIVassociated neurologic abnormality constitutional symptom . No oral hairy leukoplakia . At least 6 month prior AZT . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Abnormal chest xray , consistent active opportunistic infection . Hypersensitivity thymopentin . Significant chronic underlie medical illness . Grade 2 bad peripheral neuropathy . Concurrent Medication : Excluded : HIV vaccine . Investigational nonFDA approve medication . Immunomodulatory therapy . Experimental therapy . Any antiretroviral therapy AZT , ddI , ddC , d4T , 3TC . Patients follow prior condition exclude : Herpes zoster ( within past year ) . Recurrent ( &gt; one episode ) oral candidiasis ( confirm ) . Vulvovaginal candidiasis ( persistent , frequent , poorly responsive therapy ) . Bacillary angiomatosis . Listeriosis . Idiopathic thrombocytopenia purpura . Prior Medication : Excluded time prior study entry : More one dose thymopentin . Excluded within 30 day prior study entry : HIV vaccine . Investigational nonFDA approve medication . Immunomodulatory therapy . Experimental therapy . Any antiretroviral therapy AZT , ddI , ddC , d4T , 3TC . Required : Prior AZT ( &gt; = 300 mg/day ) least 6 month ; current regimen ( combination approve nucleoside analogue ) least 4 week . Significant active alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Thymopentin</keyword>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
</DOC>